Schizophrenia and Schizoaffective Disorders
Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.
How Magicians Illuminate the Science of Creativity and Mental Health
Magicians showed lower impulsive nonconformity and psychotic traits than other creatives and the general population.
Effect of Care Burden and Personality Traits of Caregivers on Treatment Compliance and Functionality of Patients With Schizophrenia
The temperament and character traits of caregivers may affect the social functionality of patients with schizophrenia.
Medication Adherence in a Transdiagnostic First-Episode Psychosis Sample
Thirty percent of patients with first-episode psychosis showed non-adherence to medication over a period of up to 5½ years. Treatment factors such as the type or dose of antipsychotic were not associated with adherence level.
Recent JCP Articles
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis
Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier in the course of schizophrenia in adults.
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study
A new formulation of injectable aripiprazole for administration every 2 months showed similar rates of treatment-emergent adverse events to aripiprazole once-monthly 400 mg. Patients in both groups remained clinically stable throughout the 32-week period.
The Impact of Clozapine Delay on Clinical Outcomes in Schizophrenia
Clozapine is the drug of choice for treatment-resistant schizophrenia, but delays in initiation and underutilization may hinder its effectiveness. This study examined whether delay in clozapine initiation led to poorer clinical outcomes.
Recent PCC Articles
Cognition in Schizophrenia: A Systematic Review of Wechsler Adult Intelligence Scale Studies
This systematic review showed specific cognitive functioning in individuals diagnosed with schizophrenia, highlighting lower than average performance compared to healthy controls regarding executive cognitive functions such as information processing, attention, and working memory capacity.
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depression, Schizophrenia, and Obsessive-Compulsive Disorder: An Umbrella Meta-Analysis
In treatment-resistant depression, repetitive transcranial magnetic stimulation had higher odds of response and remission rates compared to sham.
Psychosis in a Patient With Sturge-Weber Syndrome: A Case Report and Literature Review
This report describes a patient with Sturge-Weber syndrome who developed progressive psychosis over time and received a diagnosis of schizophrenia.
Front of Mind News
The Weekly Mind Reader: Urinary Retention As a Clozapine Side Effect
Understanding the potential adverse effects of clozapine is crucial, even if, like urinary retention, they are relatively rare.
The Weekly Mind Reader: Catatonia Challenges and Solutions
The challenges of managing catatonia, its legal implications, treatment complexities, and the significance of patient advocacy.
The Weekly Mind Reader: The Cost of Schizophrenia Exceeds $170 Billion Annually
Schizophrenia's profound challenges lead to substantial economic burdens, costing billions annually in the US healthcare system and broader economy.
Emerging Treatment Approaches for Schizophrenia Show Promise
Leslie Citrome, MD, MPH discusses treatments for schizophrenia that will herald a new era in its management.
EMERGENT Trial Data For KarXT Shows Promise in Schizophrenia
KarXT shows potential in alleviating schizophrenia symptoms while effectively managing side effects, offering hope for improved outcomes.